Please use this identifier to cite or link to this item: http://earsiv.odu.edu.tr:8080/xmlui/handle/11489/4019
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCetinkol, Yeliz-
dc.date.accessioned2024-03-15T06:47:40Z-
dc.date.available2024-03-15T06:47:40Z-
dc.date.issued2012-
dc.identifier.citationÇetinkol, Y. (2012). HBsAg, Anti-HCV and Anti-HIV Seroprevalence of the patients apply to Kars Public Hospital. VIRAL HEPAT. DERG., 18(2), 76-80. https://doi.org/10.4274/Vhd.98608en_US
dc.identifier.issn1307-9441-
dc.identifier.issn2147-2939-
dc.identifier.urihttp://dx.doi.org/10.4274/Vhd.98608-
dc.identifier.urihttps://www.webofscience.com/wos/woscc/full-record/WOS:000217194500009-
dc.identifier.urihttp://earsiv.odu.edu.tr:8080/xmlui/handle/11489/4019-
dc.descriptionWoS Categories: Medicine, General & Internalen_US
dc.descriptionWeb of Science Index: Emerging Sources Citation Index (ESCI)en_US
dc.descriptionResearch Areas: General & Internal Medicineen_US
dc.description.abstractObjective: In this study, it was aimed to present the information about seroprevalance rates of our city by determining the distributions of HBsAg, antiHBs, anti-HCV, anti-HIV seropositivies according to gender, age and risk factors (dialysis patients, the preoperative tests, blood donors, outpatients) in the patients who admitted to the Kars State Hospital between July 2007 and July 2008. Materials and Methods: The electronic records of 29.227 patients were retrospectively evaluated. All tests were performed using chemiluminescent microparticle immunoassay method. In total, 12965 patients were tested for HBs Ag, 11763 for anti-HCV and 10491 for anti-HIV tests. Results: The seropositivity rates for HBsAg, anti-HCV, anti-HIV were 4.6%, 1.5%, and 0.009%, respectively. Conclusion: The seropositivity rates for HBsAg and anti-HCV in our region were comparable to those seen across Turkey. Whereas, the seropositivity rates for antiHIV were lower than the average rate in Turkey. When the risk factors for HBsAg and anti-HCV seropositive patients (dialysis patients, the preoperative examination, blood donors, outpatients) were taken into consideration, the rates of seropositivity in dialysis patients were found to be significantly higher than the other groups. No statistically significant difference was found in the rates of seropositivity in the groups with other risk factor.en_US
dc.language.isoengen_US
dc.publisherGALENOS YAYINCILIK-FINDIKZADEen_US
dc.relation.isversionof10.4274/Vhd.98608en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectHBsAg, anti-HBs, anti-HCV, anti-HIV, seroprevalenceen_US
dc.subjectHEPATITIS-B-VIRUS, BLOOD-DONORS, PREVALENCE, INFECTION, REGION, TURKEY, MERSIN, AGEen_US
dc.titleHBsAg, Anti-HCV and Anti-HIV Seroprevalence of the patients apply to Kars Public Hospitalen_US
dc.typearticleen_US
dc.relation.journalVIRAL HEPATIT DERGISI-VIRAL HEPATITIS JOURNALen_US
dc.contributor.departmentOrdu Üniversitesien_US
dc.identifier.volume18en_US
dc.identifier.issue2en_US
dc.identifier.startpage76en_US
dc.identifier.endpage80en_US
Appears in Collections:Temel Tıp Bilimleri

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.